Austin Health

Title
A case-control study of end-of-life treatment preferences and costs following advance care planning for adults with end stage kidney disease.
Publication Date
2019-02
Author(s)
Sellars, Marcus
Morton, Rachael L
Clayton, Josephine M
Tong, Allison
Mawren, Daveena
Silvester, William
Power, David
Ma, Ronald
Detering, Karen M
Subject
advance care planning
chronic kidney disease
conservative care
cost-effectiveness
nephrology
Type of document
Journal Article
DOI
10.1111/nep.13230
Abstract
To examine the efficacy of advance care planning (ACP) to improve the likelihood that end-stage kidney disease (ESKD) patient's preferences will be known and adhered to at end-of-life. A case-control study of a nurse-led ACP program in adults with ESKD from a major tertiary hospital. The primary outcome was the proportion of patients whose preferences were known (by substitute decision maker and/or clinicians) and adhered to by their treating doctors. Secondary measures were health system resource use and costs ($AUD) for a nurse-led ACP intervention in the last 12-months of life. In total, 57 cases (38 men, mean age 73.8 years) and 57 historical controls (38 men, mean age 74.0 years) were included. Cases (38/57, 67%) were significantly more likely than controls (15/57, 26%) to have their preferences known and adhered to by their treating doctor at end-of-life (p<0.001). Cases (33/40, 83%) were also significantly more likely to withdraw from dialysis in accordance with their preferences than controls (11/33, 33%) (p<0.001). For cases, the average hospital costs in the last 12 months of life was AUD $99,077 (SD = $71,002) per patient. The total cost of the ACP program in 2010/11 was AUD $26,821. ACP was associated with improvements in end-of-life care preferences known and adhered to for people with ESKD.
Link
Citation
Nephrology 2019; 24(2): 148-154
Jornal Title
Nephrology

Files:

NameSizeformatDescriptionLink